While studies of PPARγ/α agonists in relation to diabetes have been done before (185), there has been a greater focus in more recent years on how these dual agonists can treat diabetes with greater efficacy while also limiting the risk of heart failure (76), utilizing both pro and anti-inflammatory effects to our advantage. Here, PPARG is linked to diabetes mellitus.